Hidradenitis suppurativa burden of disease tool: Pilot testing of a disease-specific quality of life questionnaire - 13/12/17
Funding sources: None. |
|
Dr Patel serves as a consultant/advisory board member for AbbVie. Dr Merola serves as consultant/advisor for Biogen IDEC, AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Janssen, UCB, Kiniksa, Momenta, and Mallinckrodt, is on the advisory board for Biogen IDEC, AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Janssen, UCB, Kiniksa, Momenta, and Mallinckrodt, is a speaker for AbbVie and Eli Lilly, is an investigator for Biogen IDEC, Amgen, Pfizer, and Boehringer Ingelheim, has received a grant from Biogen IDEC, and is a licensed outcome measure for AbbVie. Drs Pinard, Vleugels, and Joyce have no relevant financial interests to report, and no potential conflict of interest to declare. |
Vol 78 - N° 1
P. 215 - janvier 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?